UNSPSC 51313112: Cetirizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O047KTOA, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride, (+-)- but more generally known as cetirizine dihydrochloride, which bears US NIH Compound Identifier 55182.

UNSPSC 51313112 Cetirizine hydrochloride is a Commodity code that nominally designates a specific antihistamine pharmaceutical product, but recent state and local procurement activity under this code does not reflect actual purchases of cetirizine. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS posted June 30, 2026—solicits naloxone and drug deactivation systems, which fall outside the code's stated scope. This mismatch suggests either a data-tagging error in the state procurement system or that the code is being used as a catch-all for pharmaceutical and health-related supplies beyond its narrow commodity definition. State and local governments do source specific medications and pharmaceuticals through UNSPSC coding, typically for public health departments, emergency services, correctional facilities, and health-focused county agencies, but this particular code shows minimal relevant recent activity.

Seminole County represents the only recent sourcing activity under this code, with the county seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB was released with a response deadline of July 26, 2023 (notably predating the current date), and the procurement includes standard compliance requirements including E-Verify and drug-free workplace certification, with potential FEMA funding introducing federal environmental compliance obligations. The contract structure offers an initial two-year term with a one-year renewal option and does not specify set-asides for disadvantaged enterprises. Without additional recent opportunities in the block, geographic concentration cannot be characterized beyond this single Florida jurisdiction, and pursuit decisions under this code should treat the mismatch between the nominal commodity (cetirizine) and the actual recent procurement (naloxone and deactivation systems) as a signal to verify scope alignment before bidding.